| 1.16 0.09 (8.41%) | 12-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.59 | 1-year : | 1.84 |
| Resists | First : | 1.36 | Second : | 1.58 |
| Pivot price | 1.34  |
|||
| Supports | First : | 1.01 | Second : | 0.84 |
| MAs | MA(5) : | 1.18 |
MA(20) : | 1.35 |
| MA(100) : | 1.31 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.5 |
D(3) : | 9.7 |
| RSI | RSI(14): 39 |
|||
| 52-week | High : | 3.5 | Low : | 1.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RNTX ] has closed above bottom band by 17.9%. Bollinger Bands are 50.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.19 - 1.2 | 1.2 - 1.21 |
| Low: | 1.03 - 1.04 | 1.04 - 1.05 |
| Close: | 1.14 - 1.16 | 1.16 - 1.17 |
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Thu, 11 Dec 2025
Rein Therapeutics Ends Key Financial Agreements - TipRanks
Thu, 11 Dec 2025
Rein Therapeutics ends agreements with Yorkville, incurs no penalties - Investing.com
Mon, 03 Nov 2025
Rein Therapeutics Inc. (RNTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Mon, 03 Nov 2025
Why Is Rein Therapeutics Stock Trading Higher On Monday? - Benzinga
Mon, 03 Nov 2025
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewswire
Wed, 29 Oct 2025
Rein Therapeutics Inc. Stock (RNTX) Opinions on Institutional Investments and Funding Deals - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 26 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 32.6 (%) |
| Shares Short | 426 (K) |
| Shares Short P.Month | 63 (K) |
| EPS | -2.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.9 % |
| Return on Equity (ttm) | -83.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.4 |
| PEG Ratio | 0 |
| Price to Book value | 23.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|